Table 3.
Brief review of literature on the treatment of unresectable HCC with TACE in patients with unresectable HCC
| Study | No. of patients | Child-Pugh class | CR and PR | Survival |
|---|---|---|---|---|
| Lo et al. [60] | 80 (40 TACE) | NA, OKUDA I (n = 19)/II (n = 21) | 39% (WHO and/or AFP) | 2 years 31% |
| Llovet et al. [59] | 112 (40 TACE) | A (n = 31)/B (n = 9) | 35% (WHO) | 2 years 63% |
| Camma et al. [75] | 2446 (2268 TACE) | A (59%) | 38.7% (WHO) | OR 0.54, P = 0.015 |
| Llovet et al. [59] | 1443 (545 TACE) | A (82%) | 35% (WHO) | 2 years 41%, OR 0.53, P = 0.017 |
| Yuen et al. [76] | 96 (80 TACE) | A (n = 64)/B(n = 16) | 28%a | 2 years 78.8%, median 31.2 months |
| Takayasu et al. [61] | 8542 | A (51%)/B(39%)/C (10%) | NA | 2 years 63%, median 34 months |
| Brown et al. [77] | 209 | A (n = 132)/B (n = 65)/C (n = 4) | NA | Median 12.6 months |
| Liapi et al. [13] | 347 | A (66%)/B (31%)/C (3%) | 32% (RECIST) | Median 20.25 months |
CR complete response, PR partial response, WHO World Health Organization, AFP alfa-fetoprotein, OR odds ratio, NA not applicable
a
Tumor size by angiogram